Adipose-Derived Stem Cells From Patients With Ulcerative Colitis Exhibit Impaired Immunosuppressive Function

Area of Science:

• Immunology
• Stem Cell Biology
• Gastroenterology

Background:

• Adipose-derived stem cells (ADSCs) are explored for ulcerative colitis (UC) treatment due to their immune-modulating properties.
• Concerns exist regarding potential defects in ADSCs from patients with inflammatory or autoimmune diseases, impacting their therapeutic efficacy.

Purpose of the Study:

• To compare the functional and immunosuppressive characteristics of ADSCs from healthy donors (H-ADSCs) and UC patients (P-ADSCs).
• To evaluate the therapeutic potential of P-ADSCs in mouse models of colitis.

Main Methods:

• Comparative analysis of ADSC morphology, proliferation, differentiation, and immunomodulatory functions (cytokine secretion, immune cell suppression).
• Assessment of P-ADSC immunosuppressive capacity via peripheral blood mononuclear cell proliferation assays and cytokine analysis.
• In vivo efficacy testing of P-ADSCs versus H-ADSCs in acute and chronic colitis mouse models.

Main Results:

• P-ADSCs demonstrated reduced proliferative and differentiation capacities compared to H-ADSCs.
• P-ADSCs exhibited significantly diminished immunosuppressive functions, including lower inhibition of T-cell proliferation and reduced secretion of key immunomodulatory factors like prostaglandin E2.
• In colitis models, P-ADSCs showed weaker therapeutic effects than H-ADSCs, evidenced by increased disease activity and poorer histological outcomes.

Conclusions:

• ADSCs from UC patients possess inherent functional defects, particularly in immunosuppression, linked to donor metabolic characteristics.
• The findings challenge the suitability of autologous ADSC transplantation for UC treatment, highlighting potential limitations in immune modulation.